论文部分内容阅读
目的探讨重组组织型纤溶酶原激活剂早期静脉溶栓对急性脑梗死的治疗效果。方法收集我院2014年3月~2015年9月入院的40例急性脑梗死患者按随机数字法分为两组。对照组患者给予常规活血化瘀治疗，实验组患者采取重组组织型纤溶酶原激活剂(rt-PA)0.8 mg/kg静脉溶栓治疗。结果实验组患者治疗痊愈率明显性高于对照组患者，存在明显性差异，具有统计学意义(<0.05)；实验组患者治疗总有效率明显性高于对照组患者，存在明显性差异，具有统计学意义(<0.05)；实验组患者治疗后1、7、14 d NIHSS评分分别与对照组行组间比较，显著性低于对照组患者NIHSS评分，存在显著性差异，具有统计学意义(<0.01)。结论重组组织型纤溶酶原激活剂早期静脉溶栓对急性脑梗死的治疗效果显著。“,”Objective To investigate the therapeutic effect of early intravenous thrombolysis with recombinant tissue type plasminogen activator in patients with acute cerebral infarction.Methods In our hospital from March 2014 to September 2015,40 patients with acute cerebral infarction were randomly divided into two groups according to the random number method.The control group were treated with routine blood circulation treatment,the patients in the experimental group take of plasminogen activator recombinant tissue type plasminogen activator (RT PA)agent 0.8 mg/kg intravenous thrombolytic therapy.Results Patients in the experimental group treatment cure rate was significantly higher than that of the control group,there was a significant difference,with statistical significance ( <0.05);treatment,the patients in the experimental group the total efficiency is obviously higher than that of the control group,there was a significant difference,with statistical significance ( <0.05).After treatment,the patients in the experimental group 1,7,14,NIHSS score respectively and the control group,group,significantly lower than control group patients NIHSS score,there are significant differences,with statistical significance ( <0.01).Conclusion Early intravenous thrombolysis with recombinant tissue type plasminogen activator has significant effect on the treatment of acute cerebral infarction.